1. Home
  2. ONCO vs GCTK Comparison

ONCO vs GCTK Comparison

Compare ONCO & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$0.81

Market Cap

2.8M

Sector

Health Care

ML Signal

N/A

GCTK

GlucoTrack Inc.

N/A

Current Price

$0.37

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ONCO
GCTK
Founded
2018
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
2.5M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
ONCO
GCTK
Price
$0.81
$0.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
192.6K
17.6M
Earning Date
06-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
22.80
N/A
EPS
N/A
2.65
Revenue
$815,371.00
$589,462.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.14
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.25
52 Week High
$6.73
$14.14

Technical Indicators

Market Signals
Indicator
ONCO
GCTK
Relative Strength Index (RSI) 45.96 46.86
Support Level $0.62 $0.28
Resistance Level $0.86 $0.68
Average True Range (ATR) 0.09 0.13
MACD 0.01 -0.01
Stochastic Oscillator 47.82 19.37

Price Performance

Historical Comparison
ONCO
GCTK

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

Share on Social Networks: